Burn News and Research

RSS

GenVec announces data from respiratory syncytial virus vaccine program

GenVec, Inc. (Nasdaq: GNVC) announced today that data were presented on GenVec's respiratory syncytial virus (RSV) vaccine program at the "Keystone Symposium on Viral Immunity and Host Gene Influence", which is taking place in Keystone, Colorado from March 21-26, 2012.

26 Mar 2012

U-M teams up with India's top academic medical programs for trauma care research

The University of Michigan Health System is teaming up with one of India's top academic medical programs to collaborate on trauma care research and to foster exchanges of medical personnel and ideas.

20 Mar 2012

Sanofi enters definitive agreement to acquire Pluromed

Sanofi and Pluromed Inc. announced today that they have entered into a definitive agreement under which Sanofi is to acquire Pluromed Inc., a medical device company based in Woburn, Massachusetts.

17 Mar 2012

Extremely contagious RSV virus can lead to serious illness in young children

Respiratory Syncytial Virus (RSV) is a common virus that infects the lungs and breathing passage ways. Though it may only produce minor cold symptoms in adults, it can lead to serious illness in young children and those with compromised immune systems.

17 Mar 2012

CSL Behring initiates FCH Phase III trial to control bleeding during cardiovascular surgery

CSL Behring announced today that the first patient has been treated as part of the REPLACE Phase III clinical trial evaluating the efficacy and safety of fibrinogen concentrate (Human) (FCH) in controlling microvascular bleeding during aortic aneurysm surgery.

16 Mar 2012

GenVec 2011 net loss decreases to $7.4 million

Today GenVec, Inc. announced financial results for the fourth quarter and year ended December 31, 2011. For the year ended December 31, 2011, the Company reported a net loss of $7.4 million, or $0.58 per share, compared with a net loss of $12.3 million, or $0.97 per share, for the year ended December 31, 2010.

15 Mar 2012

MDxHealth fourth quarter total revenues increase 48% to €0.9M

MDxHealth SA, a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced results for Q4 and full year 2011.

15 Mar 2012

New topical gel decreases amount of time needed to treat actinic keratosis

A new topical gel now available by prescription significantly decreases the amount of time needed to treat actinic keratosis, a skin condition that is a common precursor to skin cancer, according to a multi-center trial led by researchers at Mount Sinai School of Medicine.

15 Mar 2012

Varicose veins may be a simple cosmetic issue or a serious medical problem

With spring break shorts and swimsuit season coming up, many people will soon show off their legs for the first time in months, and for some, that also means deciding what to do about unsightly varicose veins. The bulging purple or blue lines may be simply a cosmetic issue, or they could be a sign of a serious medical problem, says Mayo Clinic vascular surgeon Peter Gloviczki, M.D.

14 Mar 2012

InflammaGen Therapeutics initiates Shok-Pak Phase 2 pilot study

InflammaGen Therapeutics, a development-stage, critical care company initially focused on the diagnosis, treatment and prevention of multi-organ failure (MOF), announced today that the Company has initiated a 200-patient Phase 2 pilot study to examine the efficacy and safety of InflammaGen Shok-Pak as a potential treatment for critically ill patients in the Intensive Care Unit.

12 Mar 2012

New Burn Medical Education app for physicians, students

A newly released mobile app designed to educate medical students, physicians and health care workers around the globe on how to care for burn victims is one of a fast-growing number of medical apps being developed at Johns Hopkins Medicine.

12 Mar 2012

PharmAthene revenue increases to $24.3M for year ended December 31, 2011

PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, today reported its financial and operational results for the year ended December 31, 2011.

9 Mar 2012

Ordinary fat cells can be reengineered to burn calories

In the war against obesity, one's own fat cells may seem an unlikely ally, but new research from the University of California, San Francisco (UCSF) suggests ordinary fat cells can be reengineered to burn calories.

8 Mar 2012

Celldex fourth quarter net loss increases to $12.7 million

Celldex Therapeutics, Inc. today reported financial results for the fourth quarter and the year ended December 31, 2011.

8 Mar 2012

Nitrogen balance occurs with a precise 24-hour rhythm in mammals

Researchers at Case Western Reserve University School of Medicine demonstrated that nitrogen balance, the process of utilizing amino acids and disposing of their toxic byproducts, occurs with a precise 24-hour rhythm - also known as circadian rhythm - in mammals. Disruption of this cycle has a direct impact on survival of organisms, and may predispose one to life altering diseases including diabetes and cardiovascular disease.

7 Mar 2012

Pten gene can also fight against obesity, ageing process

This result, obtained after five years' research, is published in leading journal Cell Metabolism. The authors, led by Manuel Serrano (CNIO), believe it will open the door to new therapeutic options not only against cancer, but against obesity and even the ageing process.

7 Mar 2012

Stereotaxis fourth quarter net loss increases to $5.5M

Stereotaxis, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2011.

6 Mar 2012

Access full year 2011 revenues increase 284%

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology and cancer supportive care,announced preliminary revenue results for fourth quarter 2011 and full year 2011. Fourth quarter MuGard product sales increased 400% over third quarter product sales.

5 Mar 2012

Study: Bioavailability similar among four subcutaneous IgG preparations

Data presented by CSL Behring today suggest that the bioavailability of immunoglobulin G (IgG) therapies is consistent when patients with primary immunodeficiencies switch from one IgG product to another by the subcutaneous route.

5 Mar 2012

Ten symptoms and signs that a child may need a doctor

Unfortunately, kids get sick. Fighting a virus or common cold is good for a child's immune system and can help build antibodies that protect them from dangerous illnesses. Still, there are times when that tummy ache or cough may require medical attention.

2 Mar 2012